Hypophyseal Involvement in Immunoglobulin G4-Related Disease: A Retrospective Study from a Single Tertiary Center
Table 4
Follow-up of IgG4-RH patients 1–8.
ID
Initial therapeutic regimens
Length of initial treatment (months)
T1 (months)
T2 (months)
Response
Pituitary function recovery
GC regimens
Immunosuppressive regimens
Clinical features
MRI features
Relapse
Anterior lobe
Posterior lobe
1
Dex 1.5 mg (tid)
n/a
2.0
2.0
n/a
+
+
+
n/a
−
2
Pred 40 mg (qd)
n/a
5.4
1.3
n/a
+
+
−
−
−
3
MP 40 mg (qd)
CTX 50 mg (qod)
48.6
6.5
33.6
+
+
−
−
−
4
MP 40 mg (qd)
CTX 400 mg (qw)
26.4
1.4
7.7
+
+
−
n/a
−
5
Pred 60 mg (qd)
n/a
7.5
1.2
2.8
+
+
−
−
−
6
Pred 40 mg (qd)
n/a
4.0
1.4
n/a
+
+
−
n/a
−
7
Pred 40 mg (qd)
n/a
12.6
0.9
n/a
+
+
−
−
n/a
8
Pred 50 mg (qd)
CTX 50 mg (qd)
5.0
1.4
n/a
+
+
+
n/a
±
GC: glucocorticoids; T1: duration of the initial therapy before having a symptomatic/radiological response; T2: duration of the initial therapy before serum IgG4 was normalized; Dex: dexamethasone; Pred: prednisone; MP: methylprednisolone; CTX: cyclophosphamide; n/a: not applicable; +: remission; ±: partial; −: negative.
